Compounded semaglutide vs Wegovy and Ozempic: what is different
A plain comparison of compounded semaglutide, Wegovy and Ozempic: approval status, price, format and how each one is prescribed and dispensed.
Guides · Weight loss · Dr. Pat Taylor, MD · Updated Sep 17, 2026
Semaglutide reaches patients in the United States in three different ways, and the differences are worth understanding before you start. Wegovy and Ozempic are the FDA approved prescription products. Compounded semaglutide is a separately prepared prescription medication made by a licensed compounding pharmacy for an individual patient.
This guide covers what is actually different between them: approval status, price, format, and the path you take to get each one. It does not compare or equate what is inside them, because that is not a comparison a patient guide can responsibly make.
Three semaglutide products explained
Wegovy
According to the Wegovy prescribing information on DailyMed, WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. The label states that WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events, described as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with established cardiovascular disease and either obesity or overweight. The label also lists reducing excess body weight and maintaining weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Ozempic
According to the Ozempic prescribing information on DailyMed, OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The label also lists reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease, and reducing the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.
That is the cleanest difference between the two brand products. They carry different approved indications, and the label is the document that defines what each one is approved to treat.
Compounded semaglutide
Compounding is described by the FDA as a practice in which a licensed pharmacist or a licensed physician combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. Compounded semaglutide is therefore a separately prepared prescription, made by a licensed compounding pharmacy after a licensed provider writes for it.
Compounded medications are not FDA approved finished products and are custom-prepared by licensed compounding pharmacies, which means the U.S. Food and Drug Administration (FDA) does not evaluate them for safety or effectiveness. A licensed provider determines eligibility.
Approval status
This is the difference that matters most, and it is also the one most often blurred in marketing.
The FDA states plainly that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. The same FDA page notes that although compounded drugs can serve an important medical need for certain patients, they also may pose risks to patients.
Wegovy and Ozempic went through FDA review and carry approved labeling, which is why you can look up their indications, warnings and administration details on DailyMed. Compounded semaglutide does not have that label, because it is prepared for an individual patient rather than manufactured and approved as a finished product.
What that means for you in practice: with a compounded prescription, the quality of your care depends heavily on the provider who evaluates you and the licensed pharmacy that prepares the medication. Ask who the pharmacy is. Ask who signs the prescription. Ask how to reach a clinician if something feels off.
Price
Pricing is the second reason most people compare these options, and the numbers come from different places depending on which product you are looking at.
For the brand product, NovoCare publishes self-pay terms. As of 2026-09-16, NovoCare states that patients new to the Wegovy Savings offer or NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg, described as an offer for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for Wegovy HD 7.2 mg. NovoCare adds that eligibility and restrictions apply, and that Novo Nordisk reserves the right to modify or cancel this program at any time.
Two things follow from that. First, published self-pay pricing can change, so check the current terms before you plan a budget. Second, intro pricing that resets after a set number of fills means the number you see first is not always the number you pay in month three. Read the terms, not the headline.
If you have insurance, coverage for a brand GLP-1 depends on your plan and your diagnosis, and the only reliable answer comes from your plan documents or your pharmacy.
Belle publishes current pricing for compounded semaglutide live on the site, so the number you see is the number in effect today.
Pens vs vials
Format is a practical difference that affects how the medication arrives and how you handle it at home.
For Wegovy, the NovoCare self-pay terms define one month as 1 box of 4 pens, as of 2026-09-16. That gives you a sense of how the brand product is packaged and supplied for a monthly fill.
Compounded semaglutide is prepared by a licensed compounding pharmacy on a prescription, so the presentation depends on what the provider writes and what the pharmacy supplies. Belle lists exactly what is included on the compounded semaglutide page, and your provider will confirm the details with you before anything ships.
Neither format is automatically better. Some people prefer the simplicity of a prefilled device. Others do not mind drawing a dose. What matters more is that you understand how to store the medication, how to handle it safely and who to contact with questions.
How you get each one
All three require a prescription from a licensed provider. The routes differ.
- Wegovy or Ozempic through traditional care: you see a clinician, the prescription goes to a pharmacy, and you pay through insurance or through a manufacturer self-pay route such as the NovoCare terms described above.
- Wegovy or Ozempic through a telehealth visit: the same brand product and the same pharmacy path, with the consultation happening online instead of in an office.
- Compounded semaglutide through a telehealth clinic: you complete an intake with your health history, a licensed provider reviews it, and if treatment is appropriate the prescription goes to a licensed compounding pharmacy that prepares it and ships it to you.
At Belle, the intake is online, a licensed provider reviews every case, and you can message the care team with questions once you start. If you are not a good candidate, the provider will say so. You can see the wider program on the weight loss treatments page, and food support is available through nutrition guidance.
One warning worth repeating: buy only through a licensed provider and a licensed pharmacy. Anything sold without a prescription, marketed as research material, or shipped from an unverified seller sits outside the system described on the FDA compounding page.
Below are the questions the Belle team hears most when people are choosing between a compounded prescription and a brand product. For anything specific to your health history, medications or goals, talk with a licensed provider. You can also browse the Learn hub for more comparisons and cost breakdowns.
Key points
- Wegovy and Ozempic are the FDA approved prescription products. Compounded semaglutide is a separately prepared prescription medication made by a licensed compounding pharmacy for an individual patient.
- The FDA states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed.
- The two brand labels cover different indications: Wegovy for weight reduction and cardiovascular risk reduction in specific groups, Ozempic for type 2 diabetes plus cardiovascular and kidney outcomes.
- Wegovy self-pay pricing published by NovoCare lists $199 per month for two monthly fills of the lower strengths, then $349 or $399 per month depending on strength, as of 2026-09-16.
- All three require a prescription. A licensed provider decides what is appropriate for you.
Q: Is compounded semaglutide FDA approved?
A: No. The FDA states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed.
Q: What is the difference between Wegovy and Ozempic?
A: They carry different approved indications. The Wegovy label lists reducing excess body weight and maintaining weight reduction long term in listed groups, plus reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. The Ozempic label lists improving glycemic control in adults with type 2 diabetes, plus listed cardiovascular and kidney outcomes in that population.
Q: How much does Wegovy cost without insurance?
A: NovoCare publishes self-pay terms. As of 2026-09-16, NovoCare states that patients new to the Wegovy Savings offer or NovoCare Pharmacy pay $199 for each month of 0.25 mg and 0.5 mg for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for Wegovy HD 7.2 mg. Eligibility and restrictions apply, and Novo Nordisk reserves the right to modify or cancel the program at any time.
Q: How much does compounded semaglutide cost at Belle?
A: Current pricing is shown live in the price table on this page and on the compounded semaglutide product page, so the number you see is the number in effect today.
Q: Who makes compounded semaglutide?
A: A licensed compounding pharmacy prepares it on a prescription for an individual patient. The FDA describes compounding as a practice in which a licensed pharmacist or a licensed physician combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.
Q: Do I need a prescription for any of these?
A: Yes. Wegovy, Ozempic and compounded semaglutide all require a prescription from a licensed provider. Products sold without a prescription should be avoided.
Q: How do I decide which route is right for me?
A: That decision belongs with a licensed provider who can review your health history, your current medications, your insurance coverage and your goals. Complete an intake and a Belle provider will tell you whether treatment is appropriate.
Education only, not medical advice.
